Attana participates at DDIP 2018, Drug Discovery Innovation Programme, Frankfurt November 29-30, 2018

The DDIP-conference focus on new technologies for improved drug development. At the conference leading professionals within industry and academy will participate. Attana will present at the scientific session and have an exhibition booth.

Attana’s participation is a continuation of the company’s ambition to increase the awareness about Attana on the market and to meet with new customers. At the conference Attana will give a scientific presentation about our technology and valuable assays, set up an exhibition booth and have several pre-schedule individual meetings with customers. To learn more about the conference and the participants please read here.

For more information, please contact:

Teodor Aastrup, CEO Attana AB
e-mail: teodor.aastrup@attana.com 
tel: + 46 8 674 57 00

The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share prices, but is of general interest for the shareholders and hence should be communicated.

Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays. Attana’s products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about Attana’s contract research services and our label free cell-based biosensors, please visit www.attana.com or contact  sales@attana.com. 

Tags: